Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 8, Number 4—April 2002
Research

Laboratory Reporting of Staphylococcus aureus with Reduced Susceptibility to Vancomycin in United States Department of Veterans Affairs Facilities1

Stephen M. Kralovic*†‡Comments to Author , Linda H. Danko*†, and Gary A. Roselle*†‡
Author affiliations: *Department of Veterans Affairs Central Office, Washington, D.C., USA; †Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio, USA; ‡University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

Main Article

Table 1

Information from reported isolates of Staphylococcus aureus with reduced susceptibility to vancomycin from United States Veterans Health Administration medical facilities, FFYa 1999

Case Inpt/Outpt/NHb Specimen Methodc (Instrumentation/panel) MIC/susceptibilityd Confirmation of susceptibility Confirmation methodology
1 Outpt Ear tissue MicroScan Walkaway version 22.01/Gram Pos Combo Panel 10 > 16 μg/mL/R Yes MicroScan Walkaway
2 Inpt/SICUe ABDf and VPg shunt MicroScan Walkaway version 22.06/Pos Combo 12 = 4 μg/mL/S No --
3 Inpt Sputum MicroScan Walkaway version 22.26/Pos Combo 14 = 4 μg/mL/S No --
4 Outpt Urine MicroScan Walkaway version 22.06/Pos Combo 12 = 4 μg/mL/S No --
5 Outpt Leg MicroScan Walkaway/Pos Combo Panel 10 = 4 μg/mL/S No --
6 Outpt Eye MicroScan Walkaway/Pos Combo Panel 10 = 8 μg/mL/(I) No --
7 Inpt Peritoneal MicroScan Walkaway/Pos Combo Panel 10 = 4 μg/mL/S No --
8 Inpt Urine MicroScan Walkaway/Pos Combo Panel 10 = 4 μg/mL/S No --
9 Outpt Wound MicroScan AutoScan/Pos Combo 11 = 4 μg/mL/S No --
10 NH Sputum MicroScan AutoScan/Pos Combo 11 = 4 μg/mL/S No --
11 NH Sputum MicroScan AutoScan/Pos Combo 11 = 4 μg/mL/S No --
12 NH Urine MicroScan AutoScan/Pos Combo 11 = 4 μg/mL/S No --
13 NH Urine MicroScan AutoScan/Pos Combo 11 = 4 μg/mL/S No --
14 NH Wound MicroScan AutoScan/Pos Combo 11 = 4 μg/mL/S No --
15 Inpt Foot wound E-test; VCNh screen plate = 4 μg/mL/S Yes Sent to CDCi; E-test
16 Outpt Synovial fluid MicroScan Walkaway/Gram Pos Combo Panel 10 = 4 μg/mL/S No --
17 Inpt/MICUj Sputum MicroScan Walkaway/Gram Pos Combo Panel 10 = 4 μg/mL/S No --
18 Inpt/ICUk Blood MicroScan AutoScan version 22.01/Pos Combo Panel 10 = 4 μg/mL/S No --
19 Inpt/MICU Urine BioMerieux Vitek VTK-R version 07.01/GPS-102 > 32 μg/mL/R Unable to determine --

aFFY=Federal fiscal year.
bInpt=inpatient; Outpt=outpatient; NH=nursing home.
c bioMerieux Vitek (Hazelwood, MO), E-test (AB Biodisk North America, Inc., Piscataway, NJ), MicroScan (Dade Behring Inc., MicroScan Division, West Sacramento, CA). Where data were available, software version of technology provided. All MicroScan methods used conventional 24-hour incubation susceptibility panels.
d Susceptibility interpretation at the reporting site (S=sensitive, I=intermediate, R=resistant).
e SICU=surgical intensive care unit.
fABD=abdominal.
gVP=Ventriculo-peritoneal.
hVCN=vancomycin.
ICDC=Centers for Diseases Control and Prevention.
jMICU=medical intensive care unit.
kICU=intensive care unit.

Main Article

1A portion of this material was presented at the 11th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America in Toronto, Ontario, Canada (Abstract #49), April 2001.

Page created: July 15, 2010
Page updated: July 15, 2010
Page reviewed: July 15, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external